J&J, Minerva amend insomnia drug agreement amid Actelion deal
MLex Summary: US biopharmaceutical company Minerva Neurosciences has announced amendments to an agreement that sees the company co-develop an insomnia drug with Johnson & Johnson. Minerva said the deal was conditional...To view the full article, register now.
Already a subscriber? Click here to view full article